BTAI BTAI
Company Profile ↓Company Overview
BTAI (BTAI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 73.2%, reflecting efficient use of shareholder capital.
Revenue has grown at a 19.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $642.00K (-71.7% YoY); net profit $-69.90M.
- Trailing 12 Months Year-on-year growth — revenue -71.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.63% |
| 1 Year: | -71.67% |
Stock Price Performance
| 1 Year: | -66.91% |
| 6 Months: | -46.46% |
| 3 Months: | -32.75% |
| 1 Month: | -19.17% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.84 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 73.2%.
- Compounding revenue at 19.6% over 5 years.
CONS
- Trading 87.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 137.00K | 206.00K | 457.00K | 341.00K | 582.00K | 1.10M | 214.00K | - | 168.00K | 120.00K | 98.00K | 256.00K | 206.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.00K | 107.00K | 11.00K | 32.00K | 283.00K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 154.00K | 13.00K | 87.00K | 224.00K | -77.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.25M | 15.87M | 14.12M | 10.51M | 10.15M |
| Operating Income | -529.00K | -565.00K | -917.00K | -4.29M | -3.24M | -5.12M | -7.42M | -8.63M | -9.13M | -15.00M | -21.43M | -24.77M | -26.38M | -27.61M | -26.81M | -31.48M | -36.29M | -38.99M | -51.20M | -52.41M | -48.30M | -24.16M | -17.30M | -15.29M | - | -10.10M | -15.85M | -14.03M | -10.28M | -10.22M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.19M | -14.89M | -26.46M | -8.07M | -8.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.99M | 4.22M | 4.37M | 4.40M | 4.20M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.25M | -19.19M | -30.91M | -12.54M | -12.69M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -529.00K | -565.00K | -917.00K | -4.28M | -3.03M | -4.89M | -7.20M | -8.47M | -9.02M | -14.91M | -21.42M | -24.75M | -26.38M | -27.62M | -26.81M | -31.47M | -37.67M | -41.80M | -52.80M | -53.52M | -50.49M | -26.79M | -8.30M | -13.65M | - | -7.25M | -19.19M | -30.91M | -12.54M | -12.69M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -1.08 | -1.11 | -0.96 | -1.12 | -1.35 | -1.49 | -1.84 | -1.83 | -1.72 | -13.89 | -3.30 | -5.15 | -3.57 | -1.50 | -2.45 | -2.18 | - | -0.54 |
| R&D Expense | 321.00K | 324.00K | 619.00K | 2.94M | 1.78M | 3.82M | 5.67M | 6.51M | 7.12M | 12.37M | 17.91M | 16.32M | 14.74M | 13.51M | 11.93M | 18.56M | 17.91M | 22.06M | 27.80M | 26.97M | 19.62M | 11.40M | 8.03M | 5.10M | - | 4.55M | 10.26M | 8.74M | - | 2.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 375.00K | 1.38M | 2.27M | 642.00K |
| Operating Income | -4.54M | -19.96M | -33.60M | -82.30M | -106.94M | -159.65M | -171.78M | -67.25M | -50.46M |
| Net Income | -4.54M | -19.27M | -32.97M | -82.17M | -106.93M | -165.76M | -179.05M | -59.60M | -69.90M |
| Diluted EPS | - | - | - | -3.79 | -4.05 | -5.92 | -98.33 | -23.51 | -5.73 |
| R&D Expense | 2.69M | 14.56M | 25.80M | 57.99M | 52.71M | 91.24M | 84.33M | 30.43M | 30.25M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2017 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.35M | 43.55M | 36.39M | 219.94M | 239.44M | 205.85M | 73.70M | 38.34M | 44.92M |
| Total Equity | -314.00K | -982.00K | 38.89M | 26.89M | 206.70M | 221.67M | 76.78M | -56.51M | -93.10M | -95.46M |
| Cash & Equivalents | - | 887.00K | 42.56M | 32.43M | 213.12M | 232.97M | 193.72M | 65.22M | 29.85M | 28.41M |
| Long Term Debt | - | - | - | - | - | - | 93.05M | 100.60M | 102.51M | 84.66M |
| Total Liabilities | - | 2.34M | 4.66M | 9.50M | 13.24M | 17.77M | 129.08M | 130.21M | 131.44M | 140.38M |
| Current Liabilities | - | 2.34M | 4.66M | 8.47M | 11.84M | 16.67M | 32.90M | 27.27M | 22.23M | 53.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.20M | -13.51M | -27.10M | -66.35M | -82.15M | -135.34M | -155.01M | -72.03M | -57.62M |
| Investing Cash Flow | - | -340.00K | -870.00K | -316.00K | -445.00K | -139.00K | -20.00K | 0 | 0 |
| Financing Cash Flow | 3.08M | 55.53M | 17.83M | 247.36M | 102.45M | 96.24M | 26.52M | 36.66M | 56.52M |
| Capital Expenditure | - | -340.00K | -870.00K | -316.00K | -445.00K | -139.00K | -20.00K | -0 | -0 |
| Free Cash Flow | - | -13.85M | -27.97M | -66.67M | -82.60M | -135.48M | -155.03M | -72.03M | -57.62M |
| Share Buybacks | - | - | - | 9.02M | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -42,572.0% | -12,448.0% | -2,967.6% | -7,860.0% |
| Net Margin % | - | - | - | - | - | -44,201.9% | -12,974.9% | -2,630.1% | -10,887.4% |
| ROE % | 462.2% | -49.6% | -122.6% | -39.8% | -48.2% | -215.9% | 316.9% | 64.0% | 73.2% |
| ROCE % | 462.0% | -51.3% | -120.3% | -39.5% | -48.0% | -92.3% | -369.9% | -417.5% | 560.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BTAI
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOR3NyV09LQ3hXYVRKQktuZk1ydDA0RXVadDk4ZUVxWWJOZ0x2N1RUcG1HakZkRlhsNnVPMzRRMVNONWdheTNibkpsZ3lxa2tFbl95RHVKMXZJRUhWemdtTVdfZ3dnamFsaXFsZ2hkMUVPSEVQX18tQTNyTmpXOFRtTHdIOFVEekxMWGhibk…
BTAI Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5HRU5rMWNub0dMZDBKeGcwdHpleS1tYkRDNjh1LUhPSVZRM3N4cWtzWFA4R2ZrdFI4ZkJYcWhYWFJpMWViSkdReDBkVWpqN3J2SlRIQ01HY2stdlBJR1Q3MEpSYk5uTEhEMDU1MjZNZFY5RFl3dFZfdE1R?oc=5" target="_blank">BTA…
BTAI Stock Gained 5% Today - What's The Latest On Its Opioid Withdrawal Treatment? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxOZWgyWWRQamRENThWdGE5WkpTbjdid1ZfSmRySDU0V1UyV25xQVBCdlRmWXFOc3I5YWF0MUVFWUpjdHduZ2hFelFJbVQwWWFOa1J0UHlkenFUejM3WnpCS05yRUhWeVdHek1VRzczQjRvUHhVZTMwTmtjQUtNckNCTUs1Y2dwWjZmcGdhan…
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxQSkhvQk8yaEMxYXpoMjJfZFVmaHc0TmhBMkxSZlBGMVFKd1VEUlgtb3ppcl8zejBvQ2w3MUdEekdNV0xfbWlPQzJMeUV1TUJoNjBOZ1NleGs4ZTFrTXhTOGQtSUlocUl4bmozUE9DT1c5b3lZSDVmV2t3VDBXZDdLaW92Sko1eFhMc015UG…
AI-driven drugmaker BioXcel raises $8M, extends investor warrants - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxOa1JJcHpOQ2p6T1VtZFpVb2FGX3Z4UFJqYnIzakppZ1ZXa0F0cEc2cV9saWdYQzZ3Z0RMcmc0c1RTNWtfNW9udzRkbWxUQzF1R1R1NUxHV0ZRWWIyUmxaWDFva3hLX0RFblQwOGlrZDdHZmVJZk9XMWtLWEh0a2tUTjNZNFdIVHhENU1scH…
$BTAI stock is down 16% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNOHI1YV82clBkaEthaDR4R1ptWVRCRTd1d2RMbWhtVmE3XzRFWU42N3JiSGl2cTdGSXFpTnNhMTA3aG5IYWFiclhtX1lGU1I1YXk1YjhNVDZTT2RTR0lfMWlWYnhBQ0tPQ3Z0TWNhOFd5cFN0bUxlZzNCRi1CVzJheTRhTUNiTFVtbUZFZ1…
BTAI — Frequently Asked Questions
What is the current share price of BTAI?
As of 2026-08-05 17:25 PDT, BTAI trades at $0.84 on NASDAQ/NYSE. Its 52-week range is $0.79 to $6.80.
What is the P/E ratio of BTAI?
BTAI trades at a trailing price-to-earnings (P/E) ratio of -0.15.
What is the return on equity (ROE) of BTAI?
BTAI has a return on equity (ROE) of 73.22%.
Is BTAI a good stock to buy?
This page provides a data-driven analysis of BTAI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.